Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation.

The Prostate·2026

Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes.

The Prostate·2025

Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines.

The Prostate·2025

Discovery of a Recurrent Frameshift Ashkenazi Jewish Founder Mutation (F722fs) in the PARP Inhibitor-sensitive MMS22L Gene Associated with Higher Risk of Prostate Cancer.

European urology focus·2025

Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry.

The Prostate·2022

A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.

European urology·2022

2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline.

The Journal of urology·2026

Factors and Reasons Influencing Compliance with Post-vasectomy Semen Analysis: A Systematic Review.

The Journal of urology·2026

Anastomotic Urethroplasty is Associated with a Lower Risk of Stricture Recurrence Compared to Buccal Mucosa Graft Onlay after Reconstruction for Radiation-Induced Bulbomembranous Urethral Stenosis.

The Journal of urology·2026

Non-Muscle Invasive Recurrence and Management During Surveillance in Patients with Muscle-Invasive Bladder Cancer Who Achieve Clinical Complete Response to Neoadjuvant Chemotherapy.

The Journal of urology·2026

TESTOSTERONE THERAPY IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER IS NOT ASSOCIATED WITH INCREASED RISK OF DISEASE PROGRESSION.

The Journal of urology·2026

A CECT-Based 2PI System as a Novel Noninvasive Prognostic Tool for Hepatocellular Carcinoma: A Dual-Validation Study.

Cancer science·2026

AI-Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma.

Medicinal research reviews·2026

Diagnosis of ovarian cancer using multiple biomarkers of CA 125, CA153, CA 19-9, CEA, HE4 and ROMA index.

Annales de biologie clinique·2026

Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma and Its Association with Pathological Grade and Stage.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP·2026

Cribriform Growth in Gleason Score 7 Prostatic Adenocarcinoma and Its Association with Pathological Parameters.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP·2026

A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines.

Pigment cell & melanoma research·2026

Related Experiment Videos

Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer

Related Concept Videos

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation.

Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes.

Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines.

Discovery of a Recurrent Frameshift Ashkenazi Jewish Founder Mutation (F722fs) in the PARP Inhibitor-sensitive MMS22L Gene Associated with Higher Risk of Prostate Cancer.

Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry.

A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.

2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline.

Factors and Reasons Influencing Compliance with Post-vasectomy Semen Analysis: A Systematic Review.

Anastomotic Urethroplasty is Associated with a Lower Risk of Stricture Recurrence Compared to Buccal Mucosa Graft Onlay after Reconstruction for Radiation-Induced Bulbomembranous Urethral Stenosis.

Non-Muscle Invasive Recurrence and Management During Surveillance in Patients with Muscle-Invasive Bladder Cancer Who Achieve Clinical Complete Response to Neoadjuvant Chemotherapy.

TESTOSTERONE THERAPY IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER IS NOT ASSOCIATED WITH INCREASED RISK OF DISEASE PROGRESSION.

A CECT-Based 2PI System as a Novel Noninvasive Prognostic Tool for Hepatocellular Carcinoma: A Dual-Validation Study.

AI-Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma.

Diagnosis of ovarian cancer using multiple biomarkers of CA 125, CA153, CA 19-9, CEA, HE4 and ROMA index.

Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma and Its Association with Pathological Grade and Stage.

Cribriform Growth in Gleason Score 7 Prostatic Adenocarcinoma and Its Association with Pathological Parameters.

A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines.

Related Experiment Videos

Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer

Related Concept Videos

Related Articles